AR040370A1 - Composiciones y metodos para determinar la susceptibilidad de un virus patogenico a los inhibidores de proteasa - Google Patents

Composiciones y metodos para determinar la susceptibilidad de un virus patogenico a los inhibidores de proteasa

Info

Publication number
AR040370A1
AR040370A1 ARP030102394A ARP030102394A AR040370A1 AR 040370 A1 AR040370 A1 AR 040370A1 AR P030102394 A ARP030102394 A AR P030102394A AR P030102394 A ARP030102394 A AR P030102394A AR 040370 A1 AR040370 A1 AR 040370A1
Authority
AR
Argentina
Prior art keywords
treatment
protease
hiv
mutation
inhibitor
Prior art date
Application number
ARP030102394A
Other languages
English (en)
Original Assignee
Virologic Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Virologic Inc filed Critical Virologic Inc
Publication of AR040370A1 publication Critical patent/AR040370A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • C12Q1/702—Specific hybridization probes for retroviruses
    • C12Q1/703—Viruses associated with AIDS
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G01N33/56988—HIV or HTLV

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • AIDS & HIV (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente provee un enfoque para desarrollar un algoritmo para determinar la efectividad de drogas anti virales basado sobre un análisis integral de los datos fenotípicos y genotípicos apareados guiados por cortes clínicos del fenotipo. En un aspecto, el algoritmo permite proveer al paciente con un tratamiento efectivo. Ayuda a predecir si un individuo infectado responderá a tratamiento con un compuesto anti viral, permitiendo de este modo disenar un régimen de tratamiento efectivo sin someter al individuo a efectos secundarios innecesarios. Además, se ahorra considerable tiempo y dinero evitando la administración de drogas no efectivas. Reivindicación 1: Un método para determinar si un HIV presenta una probabilidad aumentada de resultar hipersusceptible a tratamiento con un inhibidor de proteasa, caracterizado porque comprende detectar en la proteasa de dicho HIV la presencia o ausencia de una mutación asociada con hipersusceptibilidad a tratamiento con dicho inhibidor de proteasa en la posición de aminoácido 16, 20, 33, 36, 37, 39, 45, 65, 69, 77, 89 o 93 de una secuencia de aminoácidos de dicha proteasa, en donde la presencia de dicha mutación indica que el HIV presenta una probabilidad aumentada de resultar hipersusceptible a tratamiento con el inhibidor de proteasa, con la condición que dicha mutación no sea L33F.
ARP030102394A 2002-07-01 2003-07-02 Composiciones y metodos para determinar la susceptibilidad de un virus patogenico a los inhibidores de proteasa AR040370A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US39323402P 2002-07-01 2002-07-01

Publications (1)

Publication Number Publication Date
AR040370A1 true AR040370A1 (es) 2005-03-30

Family

ID=30000977

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP030102394A AR040370A1 (es) 2002-07-01 2003-07-02 Composiciones y metodos para determinar la susceptibilidad de un virus patogenico a los inhibidores de proteasa

Country Status (9)

Country Link
US (1) US7553618B2 (es)
EP (1) EP1552023A4 (es)
JP (1) JP2005536200A (es)
CN (1) CN1688719A (es)
AR (1) AR040370A1 (es)
AU (1) AU2003247790A1 (es)
CA (1) CA2491388A1 (es)
TW (1) TW200411180A (es)
WO (1) WO2004003512A2 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7138231B2 (en) 2000-09-15 2006-11-21 Monogram Biosciences, Inc. Means and methods for monitoring protease inhibitor antiretroviral therapy and guiding therapeutic decisions in the treatment of HIV/AIDS
US20030108857A1 (en) * 2001-06-04 2003-06-12 Parkin Neil T. Means and methods for monitoring protease inhibitor antiretroviral therapy and guiding therapeutic decisions in the treatment of HIV/AIDS
US6869759B1 (en) 1999-06-22 2005-03-22 Virologic, Inc. Means and methods for monitoring protease inhibitor antiretroviral therapy and guiding therapeutic decisions in the treatment of HIV/AIDS
US7186506B1 (en) 2000-06-12 2007-03-06 Monogram Biosciences, Inc. Means and methods for monitoring protease inhibitor antiretroviral therapy and guiding therapeutic decisions in the treatment of HIV/AIDS
US7384734B2 (en) * 2002-02-15 2008-06-10 Monogram Biosciences, Inc. Compositions and methods for determining the susceptibility of a pathogenic virus to protease inhibitors
US7993824B2 (en) 2002-07-01 2011-08-09 Monogram Biosciences, Inc. Compositions and methods for determining the susceptibility of a pathogenic virus to protease inhibitors
WO2004003512A2 (en) 2002-07-01 2004-01-08 Virologic, Inc. Compositions and methods for determining the susceptibility of a pathogenic virus to protease inhibitors
CA2672408C (en) * 2007-03-30 2019-07-23 9898 Limited Pharmacokinetic and pharmacodynamic modelling and methods for the development of phytocompositions or other multi-component compositions
CN102994459A (zh) * 2012-12-11 2013-03-27 中国人民解放军军事医学科学院微生物流行病研究所 一种对蛋白酶抑制剂耐药的hiv毒株
CN103215348B (zh) * 2013-03-19 2015-06-03 浙江大学 Hiv-1病毒蛋白酶抑制剂耐药突变检测试剂盒及方法
US10144976B2 (en) 2014-05-22 2018-12-04 Case Western Reserve University HIV-1 genotyping and coreceptor tropism assay

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0361749B1 (en) 1988-09-27 1995-02-08 Dana Farber Cancer Institute A vector comprising a replication competent HIV-I provirus and a heterologous gene
US5436131A (en) 1993-04-02 1995-07-25 Merck & Co., Inc. Color screening assay for identifying inhibitor resistant HIV protease mutants
US5766842A (en) 1994-09-16 1998-06-16 Sepracor, Inc. In vitro method for predicting the evolutionary response of a protein to a drug targeted thereagainst
US5837464A (en) 1996-01-29 1998-11-17 Virologic, Inc. Compositions and methods for determining anti-viral drug susceptibility and resistance and anti-viral drug screening
US6242187B1 (en) 1996-01-29 2001-06-05 Virologic, Inc. Compositions and methods for determining anti-viral drug susceptibility and resistance and anti-viral drug screening
US6103462A (en) 1998-05-29 2000-08-15 Institut Pasteur Rapid single-cycle assay for human immunodeficiency virus type-1 drug resistance
NZ508981A (en) 1998-06-24 2004-02-27 Virologic Inc Means and methods for monitoring nucleoside reverse transcriptase inhibitor antiretroviral therapy and guiding therapeutic decisions in the treatment of HIV/AIDS
US20030108857A1 (en) 2001-06-04 2003-06-12 Parkin Neil T. Means and methods for monitoring protease inhibitor antiretroviral therapy and guiding therapeutic decisions in the treatment of HIV/AIDS
WO2000078996A1 (en) 1999-06-22 2000-12-28 Virologic, Inc. Means and methods for monitoring protease inhibitor antiretroviral therapy and guiding therapeutic decisions in the treatment of hiv/aids
US7138231B2 (en) 2000-09-15 2006-11-21 Monogram Biosciences, Inc. Means and methods for monitoring protease inhibitor antiretroviral therapy and guiding therapeutic decisions in the treatment of HIV/AIDS
AU2001290923A1 (en) 2000-09-15 2002-03-26 Virologic, Inc. Means and methods for monitoring protease inhibitor antiretroviral therapy and guiding therapeutic decisions in the treatment of HIV/AIDS
EP1407042A4 (en) 2001-06-04 2006-02-22 Virologic Inc METHOD AND METHOD FOR MONITORING ANTIRETROVIRAL PROTEASE INHIBITOR THERAPY AND AS A GUIDANCE FOR THERAPEUTIC DECISIONS IN THE TREATMENT OF HIV / AIDS
US7384734B2 (en) 2002-02-15 2008-06-10 Monogram Biosciences, Inc. Compositions and methods for determining the susceptibility of a pathogenic virus to protease inhibitors
WO2004003512A2 (en) 2002-07-01 2004-01-08 Virologic, Inc. Compositions and methods for determining the susceptibility of a pathogenic virus to protease inhibitors
US7993824B2 (en) 2002-07-01 2011-08-09 Monogram Biosciences, Inc. Compositions and methods for determining the susceptibility of a pathogenic virus to protease inhibitors

Also Published As

Publication number Publication date
EP1552023A4 (en) 2007-04-04
TW200411180A (en) 2004-07-01
CN1688719A (zh) 2005-10-26
WO2004003512A3 (en) 2004-08-12
US7553618B2 (en) 2009-06-30
EP1552023A2 (en) 2005-07-13
AU2003247790A1 (en) 2004-01-19
JP2005536200A (ja) 2005-12-02
WO2004003512A2 (en) 2004-01-08
US20040106106A1 (en) 2004-06-03
CA2491388A1 (en) 2004-01-08

Similar Documents

Publication Publication Date Title
Couzin-Frankel Antiviral pills could change pandemic’s course
AR038557A1 (es) Composicion y metodos para determinar la susceptibilidad de un virus patogeno a los inhibidores de la proteasa
AR040370A1 (es) Composiciones y metodos para determinar la susceptibilidad de un virus patogenico a los inhibidores de proteasa
Lupfer et al. The expanding role of NLR s in antiviral immunity
Joubert et al. Chikungunya virus–induced autophagy delays caspase-dependent cell death
Hendrickson et al. Mitochondrial DNA haplogroups influence AIDS progression
Konda et al. Potential zoonotic origins of SARS-CoV-2 and insights for preventing future pandemics through one health approach
Shilaih et al. Factors associated with syphilis incidence in the HIV-infected in the era of highly active antiretrovirals
Bhushan et al. ISG15 connects autophagy and IFN-γ-dependent control of Toxoplasma gondii infection in human cells
Leung et al. Longitudinal study of surrogate aging measures during human immunodeficiency virus seroconversion
Hoffman et al. The capsule supports survival but not traversal of Escherichia coli K1 across the blood-brain barrier
Tracy et al. Enteroviruses and type 1 diabetes
Manet et al. Genetic diversity of collaborative cross mice controls viral replication, clinical severity, and brain pathology induced by Zika virus infection, independently of Oas1b
AR040371A1 (es) Composiciones y metodos para determinar la susceptibilidad de un virus patogeno a los inhibidores de proteasa
Saá et al. Frequent detection but lack of infectivity of SARS-CoV-2 RNA in presymptomatic, infected blood donor plasma
Kwok et al. Estimation of local transmissibility in the early phase of monkeypox epidemic in 2022
Qiu et al. Pyrrolidine dithiocarbamate inhibits herpes simplex virus 1 and 2 replication, and its activity may be mediated through dysregulation of the ubiquitin-proteasome system
Lin et al. Human cytomegalovirus and Epstein–Barr virus inhibit oral bacteria‐induced macrophage activation and phagocytosis
Chung et al. A large healthcare-associated outbreak of hepatitis C virus genotype 1a in a clinic in Korea
Wong et al. Evaluating antibody mediated protection against Alpha, Beta, and Delta SARS-CoV-2 variants of concern in K18-hACE2 transgenic mice
BR0011939A (pt) Recursos e métodos para monitorar terapia anti-retroviral inibidora de protease e orientar decisões terapêuticas no tratamento de hiv/aids
Ye et al. Nonpharmaceutical interventions for COVID‐19 disrupt the dynamic balance between influenza A virus and human immunity
Safarpour et al. Prevalence of Influenza Among Hajj Pilgrims: A Systematic Review and Meta-Analysis
Devi Overview of COVID-19 pandemic: transmission, epidemiology and diagnosis
Sharma et al. SARS-CoV-2: Insights from the Immunopathogenesis and Current Clinical Diagnosis and Therapeutic Strategies

Legal Events

Date Code Title Description
FB Suspension of granting procedure